Literature DB >> 3761319

Derivatives of 1-(1,3-benzodioxol-5-yl)-2-butanamine: representatives of a novel therapeutic class.

D E Nichols, A J Hoffman, R A Oberlender, P Jacob, A T Shulgin.   

Abstract

The alpha-ethyl phenethylamine derivative 1-(1,3-benzodioxol-5-yl)-2-butanamine was prepared. An asymmetric synthesis was used to prepare the enantiomers of this compound and the related alpha-methyl homologue (MDA). The racemates and enantiomers of both compounds were evaluated in the two-lever drug discrimination assay in rats trained to discriminate saline from 0.08 mg/kg of LSD tartrate. Stimulus generalization occurred with the racemate and the R-(-) enantiomer of the alpha-methyl homologue and the S-(+) enantiomer of the alpha-ethyl primary amine. No generalization occurred with the other enantiomers or with the N-methyl derivatives of either series. Human psychopharmacology studies revealed that the N-methyl derivative of the title compound was nonhallucinogenic and that it had a new, novel psychoactive effect. It is suggested that this compound is the prototype of a new pharmacologic class that may have value in facilitating psychotherapy and that this class be designated as entactogens.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3761319     DOI: 10.1021/jm00160a035

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  15 in total

Review 1.  Human hallucinogen research: guidelines for safety.

Authors:  Mw Johnson; Wa Richards; Rr Griffiths
Journal:  J Psychopharmacol       Date:  2008-07-01       Impact factor: 4.153

Review 2.  Dark Classics in Chemical Neuroscience: 3,4-Methylenedioxymethamphetamine.

Authors:  Lee E Dunlap; Anne M Andrews; David E Olson
Journal:  ACS Chem Neurosci       Date:  2018-07-12       Impact factor: 4.418

3.  A role for the mesolimbic dopamine system in the psychostimulant actions of MDMA.

Authors:  L H Gold; C B Hubner; G F Koob
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

4.  Enhancing the anti-lymphoma potential of 3,4-methylenedioxymethamphetamine ('ecstasy') through iterative chemical redesign: mechanisms and pathways to cell death.

Authors:  Agata M Wasik; Michael N Gandy; Matthew McIldowie; Michelle J Holder; Anita Chamba; Anita Challa; Katie D Lewis; Stephen P Young; Dagmar Scheel-Toellner; Martin J Dyer; Nicholas M Barnes; Matthew J Piggott; John Gordon
Journal:  Invest New Drugs       Date:  2011-08-18       Impact factor: 3.850

5.  Differences in the locomotor-activating effects of indirect serotonin agonists in habituated and non-habituated rats.

Authors:  Adam L Halberstadt; Mahálah R Buell; Diana L Price; Mark A Geyer
Journal:  Pharmacol Biochem Behav       Date:  2012-03-31       Impact factor: 3.533

6.  Comparative behavioural and neurochemical studies with a psychomotor stimulant, an hallucinogen and 3,4-methylenedioxy analogues of amphetamine.

Authors:  K M Hegadoren; M T Martin-Iverson; G B Baker
Journal:  Psychopharmacology (Berl)       Date:  1995-04       Impact factor: 4.530

7.  Amphetamine derivatives induce locomotor hyperactivity by acting as indirect serotonin agonists.

Authors:  C W Callaway; M P Johnson; L H Gold; D E Nichols; M A Geyer
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

8.  Comparative potencies of 3,4-methylenedioxymethamphetamine (MDMA) analogues as inhibitors of [3H]noradrenaline and [3H]5-HT transport in mammalian cell lines.

Authors:  T Montgomery; C Buon; S Eibauer; P J Guiry; A K Keenan; G J McBean
Journal:  Br J Pharmacol       Date:  2007-09-24       Impact factor: 8.739

9.  Drug discrimination studies with MDMA and amphetamine.

Authors:  R Oberlender; D E Nichols
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

10.  Pharmacological examination of trifluoromethyl ring-substituted methcathinone analogs.

Authors:  Nicholas V Cozzi; Simon D Brandt; Paul F Daley; John S Partilla; Richard B Rothman; Andreas Tulzer; Harald H Sitte; Michael H Baumann
Journal:  Eur J Pharmacol       Date:  2012-11-21       Impact factor: 4.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.